IMS Health alternative

    IMS Health alternative for pharmaceutical audits

    IMS Health is the legacy name for the pharmaceutical audit business that became IQVIA (IMS Health + Quintiles). Buyers still type “IMS Health alternative” because that is the label on the contract, the slide, or the habit. This page is about that pharma-audit product — not electronic medical records, not an “IMS” hospital-IT acronym, and not a retitled IQVIA alternative page.

    Keep the IMS Health / IQVIA audit when you need syndicated sell-in or sell-out in the universe it covers. Add BioNixus when you need hospital-level, account-level, or primary physician work the audit does not sell. For the current-brand IQVIA page, see IQVIA alternative.

    What is the best IMS Health alternative?

    IMS Health is the legacy name for the IQVIA pharmaceutical audit. Keep that audit for syndicated share in the universe it covers. Choose BioNixus as the IMS Health alternative when the brief is hospital-level, account-level, or primary physician research — especially in MENA. This is not an EMR “IMS” product and not a retitled IQVIA alternative page.

    • What IMS Health wasThe pharmaceutical audit company that merged into IQVIA. Buyers still use the old name on contracts and slides.
    • What it is notNot an electronic medical-records IMS. Not a synonym we use to steal the /iqvia-alternative title.
    • What BioNixus addsPrimary traces and account-level cuts the audit does not sell. Project- and country-based pricing.

    BioNixus is the IMS Health alternative for teams who still say IMS and mean the pharma audit — and still cannot see the hospital.

    Who each is for

    Stay with the incumbent when

    • You already buy an IMS Health / IQVIA audit and the question is national or channel share inside that universe.
    • The category is a standard audited pack and the panel covers your country well enough.
    • Procurement needs a continuous syndicated feed, not a one-country primary study.

    Add BioNixus when

    • The brief names a hospital, a tender, a city, or a physician segment the audit averages away.
    • Coverage is thin in a MENA market and you need primary traces — dispensing, procurement, or KOL work.
    • Someone is still saying “IMS” and meaning the pharma audit, and the missing cut is primary research.

    Alternatives compared

    Include real options. Being listed here is not an attack on the incumbent — it is a shortlist for buyers who typed this query.

    FirmBest forCoverageModel
    BioNixusPrimary pharma research beside an IMS Health / IQVIA audit — hospitals, accounts, KOLs, MENA depth48 countries — MENA, Europe, Americas, AsiaProject- and country-based. No audit-subscription minimum.
    IMS Health / IQVIA auditSyndicated pharmaceutical audits (the legacy IMS Health product now branded IQVIA)Global; MENA coverage varies by country and channelEnterprise syndicated subscription
    IQVIA (broader)RWD, CRO, and custom healthcare research on top of the auditGlobal enterpriseEnterprise programmes and subscriptions
    Ipsos HealthcareCustom physician and patient studiesGlobal healthcare networkProject-based at large-agency scale
    Oracle Life SciencesLegacy Kantar Health / Enviza capabilityGlobal life-sciences stackEnterprise healthcare data and research
    Evaluate / desk specialistsSecondary pipeline and forecast productsDesk, not in-country fieldworkReport and database subscription

    You do not have to switch off

    The usual model is the subscription you already buy, plus a custom study for the accounts, cities, and SKUs the feed cannot produce. BioNixus complements Nielsen, Kantar, GfK, IMS Health, and IQVIA. It does not replace them.

    Proposal ready within 48 hours of a brief. Email admin@bionixus.com or request a proposal below.

    Frequently asked questions

    Is IMS Health the same as IQVIA?

    IMS Health was the pharmaceutical audit company. It merged with Quintiles to form IQVIA. Buyers still say IMS Health when they mean that audit feed. This page uses IMS Health on purpose. It is not an electronic medical-records “IMS” product.

    Is this page an IQVIA alternative?

    No. The IQVIA alternative page is /iqvia-alternative. This page is the legacy IMS Health audit name. Link across; do not treat the titles as interchangeable.

    When do we keep the IMS Health audit and add BioNixus?

    Keep the audit for syndicated share in the universe it covers. Add BioNixus for hospital-level, account-level, or primary physician work — especially in MENA markets where the audit is thinner.

    Does BioNixus sell a replacement audit tape?

    We sell primary research and primary-source commercial cuts, not a cloned IMS Health tape. Complement the subscription; do not expect a drop-in file format.

    How is BioNixus priced versus an IMS Health contract?

    By project and country. No enterprise audit minimum. Proposal within 48 hours of a brief. IMS Health / IQVIA contract fees are not public — ask them directly.

    Related resources

    IQVIA alternative

    Current-brand page — do not treat this IMS Health URL as a retitle of that one.

    IQVIA alternative in Saudi Arabia

    Country complement for KSA pharma teams.

    BioNixus vs IQVIA MENA

    Side-by-side MENA capability comparison.

    Pharma companies in Saudi Arabia

    The accounts behind an audit row.

    Account-level data

    What an audit average still cannot show.

    Pricing bands

    Project- and country-based ranges.

    Need the cut the IMS Health audit does not sell?

    Primary pharmaceutical research beside the legacy IMS Health / IQVIA feed — hospitals, accounts, KOLs. Proposal ready within 48 hours of a brief.

    Planning research in Saudi Arabia?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Request a proposal